Buoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based shot for seasonal influenza, targeting four different flu strains. 

The first patents have now been enrolled into the study of the shot – codenamed mRNA-1010 – which is designed to generate antibodies against influenza A H1N1, H3N2 and influenza B Yamagata and Victoria – all of which are recommended by the World Health Organization (WHO).

Ultimately, the goal is to develop a shot that combines seasonal flu, COVID-19 and respiratory syncytial virus (RSV) protection with a single vaccine, said the biotech. It is also looking at including human metapneumovirus (hMPV), another common cause of upper respiratory tract infections.


Similar Posts

Leave a Reply

Your email address will not be published.